Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) announced a delay in its Q2 2022 financial results, citing a need for a reevaluation of its revenue recognition policy under ASC Topic 606. CEO Kirk Huntsman assured investors that the delay is not indicative of the company's overall health. Despite the delay, Vivos reported strong sales in June with record appliance sales and new provider enrollments. The company is implementing cost-cutting measures and anticipates potential positive cash flow by early 2024.
Vivos Therapeutics (NASDAQ: VVOS) announced the rescheduling of its second quarter financial results originally set for August 15, 2022, due to discussions with its accountants over revenue recognition policies under ASC Topic 606. The new date for the financial results release and conference call is expected on or before August 22, 2022. Vivos specializes in treating dentofacial abnormalities and obstructive sleep apnea through innovative, non-invasive methods.
Vivos Therapeutics (NASDAQ: VVOS) is set to announce its Q2 2022 financial results after market close on August 15, 2022. A conference call will follow at 5:00 PM ET that day to discuss the results and company milestones. Vivos specializes in treatments for dentofacial abnormalities and conditions like obstructive sleep apnea (OSA), with its Vivos Method providing a non-invasive solution to approximately 28,000 patients treated globally. The call can be accessed via dial-in or online webcast, with a replay available until August 29, 2022.
Vivos Therapeutics has received multiple Class I clearances from the Therapeutic Goods Administration in location value="LC/au"Australia for its oral appliances, enabling treatment for obstructive sleep apnea (OSA) in patients of all ages and severities. This regulatory win validates the technology's clinical safety and efficacy. Vivos aims to expand its international market presence, having previously secured clearances in the location value="LC/us"U.S. and location value="LC/ca"Canada. These advancements indicate a significant step forward for addressing the global issue of poor sleep health.
Vivos Therapeutics (NASDAQ: VVOS) has secured an exclusive distribution agreement with GM Instruments, becoming the sole U.S. and Canadian distributor of the NR6 Rhinomanometer, an FDA-approved device for assessing nasal breathing in patients with sleep and breathing issues. This collaboration is expected to enhance Vivos' revenue stream and competitive positioning by providing dentists with critical tools for evaluating and treating conditions like obstructive sleep apnea (OSA). The agreement marks a significant step in Vivos' commitment to improving patient outcomes through innovative diagnostics.
Vivos Therapeutics (NASDAQ: VVOS) presented a retrospective study at the SLEEP 2022 Annual Meeting, highlighting positive results from 786 patients using its proprietary oral appliances. The study found a 4.5% increase in transpalatal widths and an 11.1% increase in airway volume. Notably, 61.6% of the subset of patients showed a reduction of over 50% in the Apnea Hypopnea Index (AHI). Vivos' Complete Airway Repositioning and/or Expansion (CARE) therapy may represent a significant advancement for OSA treatment, offering a finite treatment duration of 12-24 months.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced two presentations at SLEEP 2022, an event hosted by the Associated Professional Sleep Societies in Charlotte, N.C., from June 4 to 8, 2022. Dr. Seth Heckman will present a retrospective study on non-surgical maxillary expansion on June 6, while Dr. J. Steven Alexander will discuss The Vivos Method's science on June 8. This participation underscores Vivos' commitment to advancing research in addressing dentofacial abnormalities and obstructive sleep apnea.
Vivos Therapeutics (VVOS) reported a revenue of $3.5 million for Q1 2022, a slight increase from $3.4 million in Q1 2021. Appliance revenue rose 19%, with 2,965 units sold. Gross profit decreased to $2.4 million, resulting in a gross margin of 68%. The company treated approximately 27,000 patients and trained over 1,500 dentists, marking significant growth. Vivos plans to open its third Pneusomnia Sleep Center in May 2022, aiming for more in the year. CEO R. Kirk Huntsman noted improvements starting in March, citing a 28% increase in appliance sales.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its financial results for Q1 2022 on May 16, 2022, after market close. A conference call will follow at 5:00 pm ET, where management will discuss results and strategic milestones. The company focuses on innovative solutions for dentofacial abnormalities and mild to moderate obstructive sleep apnea (OSA). The Vivos Method has effectively treated approximately 25,000 patients globally by trained dentists. A replay of the call will be available until May 30, 2022, along with a webcast accessible on Vivos' website.
Vivos Therapeutics, a medical technology company, announced the opening of its third Pneusomnia Sleep Center in Toluca Lake, California, in May 2022. This center aims to provide a comprehensive treatment approach for obstructive sleep apnea (OSA)/b) and related conditions, combining medical and dental expertise. Led by experienced professionals, the clinic will offer services such as The Vivos Method, home sleep testing, and mandibular advancement devices. The company promotes collaborative clinical efforts among healthcare providers to enhance access to its innovative treatments.